$LLY (Eli Lilly and Company)

$LLY {{ '2015-10-19T20:12:55+0000' | timeago}} • Announcement

The Board of Directors of $LLY has declared a dividend for the fourth quarter of 2015 of $0.50 per share, representing no change from previous quarter. The dividend is payable on Dec 10, 2015, to shareholders of record at the close of business on Nov. 13, 2015.

$LLY {{ '2017-07-12T14:48:02+0000' | timeago}} • Announcement

$LLY said that the patent expiration for Adcirca, a drug to treat blood pressure in lungs, is still expected on Nov 21, 2017, or on May 21, 2018, if the FDA approves the company's application for pediatric exclusivity.

$LLY {{ '2017-07-12T14:47:24+0000' | timeago}} • Announcement

$LLY said that its FY17 financial guidance is unaffected and there will be no change in the mid-term expectations through the remainder of the decade due to the settlement agreement in connection with the patent litigation for its erectile dysfunction drug Cialis.

$LLY {{ '2017-07-12T14:46:07+0000' | timeago}} • Announcement

$LLY reaches an agreement with generic companies with regard to the patent litigation for its erectile dysfunction drug Cialis. The patent, which is expected to expire previously on April 26, 2020, is now expected to end 1.5 years earlier (at the earliest on Sept 27, 2018).

$LLY {{ '2017-07-10T12:28:13+0000' | timeago}} • Announcement

Healthcare firm $LLY said TV entertainer Don Francisco has partnered with Lilly and Boehringer Ingelheim to launch an awareness initiative titled Basado en Hechos, to address common misconceptions about type-2 diabetes and insulin treatment. Francisco will visit cities across the country to share his personal journey of ‘living with diabetes’.

$LLY {{ '2017-07-10T11:40:23+0000' | timeago}} • Announcement

$LLY said the FDA has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, to treat advanced breast cancer, and given the NDA a Priority Review designation. $LLY plans to submit abemaciclib to European regulators in 3Q17 and to Japanese regulators before the end of 2017.

$LLY {{ '2017-07-07T12:11:45+0000' | timeago}} • Announcement

The UK Supreme Court favors the Indianapolis-based drugmaker $LLY in the litigation against Actavis related to its cancer drug Alimta. The Court said that Actavis' products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.

$LLY {{ '2017-07-06T13:03:00+0000' | timeago}} • Announcement

$LLY and Purdue University announced a strategic collaboration to conduct life science research. The five-year agreement, where $LLY will provide up to $52MM, marks Purdue's largest strategic collaboration with a single company.

$LLY {{ '2017-06-21T15:15:02+0000' | timeago}} • Announcement

$LLY announced completion of a $90MM expansion of its Biotechnology Center in San Diego, California. $LLY's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain.

$LLY {{ '2017-06-19T18:52:56+0000' | timeago}} • Announcement

$LLY BoD declared a dividend of $0.52 per share on outstanding common stock for 3Q17. The dividend is payable Sept. 8, 2017, to shareholders of record at the close of business on Aug. 15, 2017.

$LLY {{ '2017-06-15T15:01:12+0000' | timeago}} • Announcement

$LLY said patients with active psoriatic arthritis who treated with Taltz (ixekizumab) achieved significant improvement in signs and symptoms of their disease at 24 weeks when compared to placebo. Psoriatic arthritis is a chronic, progressive disease that can cause pain, swelling and stiffness of the joints.

$LLY {{ '2017-06-14T08:45:38+0000' | timeago}} • Announcement

Pharma firms $LLY and $INCY will present data from studies conducted on Olumiant, indicated for inflammatory and autoimmune diseases, at the Annual European Congress of Rheumatology being held in Madrid from June 14 to 17, 2017. Six abstracts evaluating Taltz, indicated for the treatment of psoriatic arthritis, will also be presented at the meet.

$LLY {{ '2017-06-13T19:20:27+0000' | timeago}} • Announcement

The US FDA approved $LLY’s Humalog Junior KwikPen for the treatment of diabetes. Humalog Junior KwikPen is a prefilled pen with half-unit dosing capability, enabling finer dose adjustment for those who need it. Humalog Junior KwikPen will be available in US pharmacies later in 2017.

$PFE {{ '2017-06-13T15:05:11+0000' | timeago}} • Announcement

Pharma firms $PFE and $LLY have received fast track designation from the FDA for tanezumab, an antibody against nerve growth factor. If approved, Tanezumab would be the first in the new class of non-opioid chronic medications. Meanwhile, results of an ongoing phase-3 clinical development program for tanezumab are projected to start coming in 2018.

$PFE {{ '2017-06-13T14:51:52+0000' | timeago}} • Announcement

$PFE and $LLY said that the FDA has granted Fast Track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis (OA) and chronic low back pain (CLBP). Tanezumab is an investigational humanized monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF).

$LLY {{ '2017-06-12T12:17:35+0000' | timeago}} • Announcement

Boehringer Ingelheim and $LLY will conduct a new, large clinical outcomes trial investigating Jardiance tablets for the treatment of people with chronic kidney disease. The trial will enroll people with chronic kidney disease both with and without type-2 diabetes.

$LLY {{ '2017-06-12T07:47:44+0000' | timeago}} • Announcement

$LLY announced positive results from three Phase 3 studies of its migraine treatment drug galcanezumab. Based on these results, the company will submit a Biologics License Application to the FDA for galcanezumab in 2H17, followed by submissions to other regulatory agencies around the world.

$LLY {{ '2017-06-08T20:16:08+0000' | timeago}} • Announcement

$LLY will present data from 14 abstracts, including phase-3 data for 2 investigational treatments for migraine, at the annual scientific meeting of the American Headache Society, to be held from June 8 to 11 in Boston. It will highlight phase-3 primary and secondary endpoint data in 3 late-breaking presentations for its migraine drug galcanezumab.

$LLY {{ '2017-06-08T13:39:28+0000' | timeago}} • Announcement

$LLY has entered into a collaboration with KeyBioscience for development of Dual Amylin Calcitonin Receptor Agonists, a potential new class of treatments for metabolic disorders like  type-2 diabetes. Under terms of the agreement, Lilly will receive worldwide rights to develop and commercialize the multiple molecules included in the collaboration.

$LLY {{ '2017-06-01T12:30:59+0000' | timeago}} • Announcement

$LLY said Derica Rice, EVP global services and CFO, will retire at the end of December 2017 after 27 years of service with the company. Rice is also a member of $LLY's executive committee. $LLY is considering internal and external candidates to succeed Rice.

$LLY {{ '2017-05-31T13:06:18+0000' | timeago}} • Announcement

$LLY said its Phase 3 RANGE study of CYRAMZA (ramucirumab) for the treatment of urothelial carcinoma met its primary endpoint of progression-free survival, demonstrating a statistically significant improvement. Final overall survival results are currently expected in mid-2018.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
FGEN (FibroGen, Inc.)
Tuesday, May 9 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
IMGN (ImmunoGen, Inc.)
Friday, May 5 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Thursday, May 4 2017 - 8:30pm
ZTS (Zoetis Inc.)
Thursday, May 4 2017 - 12:30pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALKS (Alkermes plc)
Thursday, April 27 2017 - 12:30pm
LLY (Eli Lilly and Company)
Tuesday, April 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, April 25 2017 - 12:30pm
ARQL (ArQule Inc.)
Tuesday, March 7 2017 - 2:00pm
SYN (Synthetic Biologics Inc.)
Thursday, March 2 2017 - 9:30pm

AlphaGraphics you may like